Last updated on: 17/05/2019
Name of organisation
1) Department/Research groupClinical Pharmacology Service
2) Organisation/affiliationPuerta de Hierro-Majadahonda University Hospital
Short Name in the inventoryClinical Pharmacology Service HUPHM
Administrative Contact
Title Miss
Last name Rodríguez Araque
First name Silvia Paloma
Address line 1Manuel de Falla 1.
Address line 228222 Majadahonda, Madrid
Address line 3
CityMadrid
Postcode28222
CountrySpain
Phone number (incl. country code)0034911916481
Alternative phone number
Fax number (incl. country code)
Scientific Contact
Title Dr
Last name Ruiz-Antoran
First name Belen
Address line 1Manuel de Falla 1.
Address line 2
Address line 3
CityMadrid
Postcode28222
CountrySpain
Phone number (incl. country code)0034911916481
Alternative phone number
Fax number (incl. country code)
Alternative Scientific Contact
Title Dr
Last name Avendaño-Solá
First name Cristina
Address line 1Manuel de Falla 1.
Address line 2
Address line 3
CityMadrid
Postcode28222
CountrySpain
Phone number (incl. country code)0034911916481
Alternative phone number
Fax number (incl. country code)
2. Description
Puerta de Hierro-Majadahonda University Hospital (HUPHM) is a public tertiary teaching hospital that belongs to the National Health Service. The Clinical Pharmacology Service was set up in 1995. The Clinical Pharmacology Service has several areas of work in clinical pharmacology and pharmacoepidemiology, pharmacovigilance (drug utilization studies, information on drugs and therapeutics, and scientific/research advice). It has several research projects sponsored by public funding agencies (pharmacoepidemiological studies and clinical trials) and also collaborates in research projects of a wide range of clinical services in the hospital (psychiatry, gastroenterology, pediatrics infectious diseases, neurology, and pneumology). Additionally gives institutional support to the Ethical Research Committee and Pharmacotherapeutics Committee of the Puerta de Hierro-Majadahonda University Hospital and other institutional boards of the national (AEMPS) and European health authority (EMEA).
3. Category
University based
Hospital based
4. Available resources
In houseVia Contacts/Network
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Disorders of the central nervous system
Endocrine disorders
Gastrointestinal tract
Gynaecology
Immunosuppression
Infectious diseases
Liver disease
Malignant disease
Musculoskeletal and joint diseases
Osteoporosis
Paediatrics
Pregnancy
Psychiatry
Respiratory diseases
Skin disorders
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Drug Utilisation
Interventional Clinical Trial
Intensive monitoring of hospital admissions
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Between 150 and 1499
8. Access to data collection resources
Capacity to conduct face-to-face interviews
Yes
In a clinic
Yes
In the community
Yes
Electronic data capture systems
Yes
System used:
SELENE
Interactive voice response systems
No
Call centre
No
9. Experience in secondary research and meta-analysis
No
10. Work with existing data resources in the past 3 years
None
11. Registries established by centre
Drug RegistryDrug RegistryElectronic Prescriptions (Famatools Madrid, ESP) in General hospital
Disease RegistrySelene Clinic - Internet Siemens Spain
Other Laboratory Registry
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
Networks registered with ENCePP
RegiSCAR
Other networks:
Network nameNationalInternationalLink to webpage
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
By EU funding schemes
15. Interest in contract research only if free to publish results
Yes
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.Calleja JL, García-Samaniego J, Ruiz-Antorán B, Trapero M, Morillas R, de la Revilla J, Erdozaín JC, Espinosa MD, Suárez D, Solá R, Romero-Gómez M, Baños F, Alvarez MA; Management of HCV Infection and Normal Transaminases Spanish Study Group. Gastroenterol Hepatol. 2012 Nov;27(11):1705-10.http://www.ncbi.nlm.nih.gov/pubmed/22742958
Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol.Ruiz-Antorán B, Agustí Escasany A, Vallano Ferraz A, Danés Carreras I, Riba N, Mateu Escudero S, Costa J, Sánchez Santiago MB, Laredo L, Durán Quintana JA, Castillo JR, Abad-Santos F, Payares Herrera C, Sádaba Díaz de Rada B, Gómez Ontañón E.Eur J Clin Pharmacol. 2010 Jun;66(6):633-41. http://www.ncbi.nlm.nih.gov/pubmed/20204337
Changes in the European normative of clinical trials (i): a chance to improve the paperwork authorization. Avendaño Solá C, Delgadillo Duarte J, Pontes García C, Cabrera García L; Grupo de Trabajo de Ensayos Clínicos de la Sociedad Española de Farmacología Clínica. Med Clin (Barc). 2012 Apr 28;138(11):493-7.
Changes in the European normative of clinical trials: towards a proportional and risk-adapted regulation.Avendaño Solá C, Delgadillo Duarte J, de Abajo FJ, Sanz N; en representación del Grupo de Trabajo de Ensayos Clínicos de la Sociedad Española de Farmacología Clínica.Med Clin (Barc). 2012 May 12;138(13):574-8.
